Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation
Abstract Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against receptor activator of nuclear factor-κb-Ligand (RANKL) denosumab was approved for treatment of adva...
Guardado en:
Autores principales: | Marc Hasenfratz, Kevin Mellert, Ralf Marienfeld, Alexandra von Baer, Markus Schultheiss, P. D. Roitman, L. A. Aponte-Tinao, Burkhard Lehner, Peter Möller, Gunhild Mechtersheimer, Thomas F. E. Barth |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7e362e1fc5aa4bdcbb09fa7a3c4adf92 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Giant-cell tumor of bone: treatment options and role of denosumab
por: Singh AS, et al.
Publicado: (2015) -
Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas KM, et al.
Publicado: (2014) -
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment
por: Yu Toda, et al.
Publicado: (2021) -
Impact of denosumab on bone mass in cancer patients
por: Brown-Glaberman U, et al.
Publicado: (2013) -
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: E Michael Lewiecki
Publicado: (2008)